Lilly’s Donanemab: US FDA's Questions Focus On Patient Selection, Dose Cessation

 
• By Sue Sutter
Stop sign
An advisory committee will consider how the donanemab Phase III trial's treatment-stopping rules should translate to clinical practice. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers